<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355990</url>
  </required_header>
  <id_info>
    <org_study_id>SAN-FIM-1</org_study_id>
    <nct_id>NCT02355990</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study</brief_title>
  <official_title>Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanoculis Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanoculis Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy&#xD;
      (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall incidence of serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure (IOP) between 6 mmHg and 15 mmHg without medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of glaucoma medications from baseline in the study eye</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pigmentary Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <arm_group>
    <arm_group_label>MIMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally Invasive Micro Sclerostomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally Invasive Micro Sclerostomy</intervention_name>
    <description>Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).</description>
    <arm_group_label>MIMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  End Stage primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary&#xD;
             glaucoma in the study eye (EGS criteria)&#xD;
&#xD;
          -  Optic nerve appearance characteristic of glaucoma in the study eye&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) of counting-fingers, hand movements, light&#xD;
             perception or no light perception due to glaucomatous loss of central vision in the&#xD;
             study eye&#xD;
&#xD;
          -  Patient is treated with 1 to 5 hypotensive medications in the study eye&#xD;
&#xD;
          -  Unsatisfactory medicated IOP (≥ 18 mmHg) at the screening visit in the study eye&#xD;
&#xD;
          -  Shaffer grade ≥ III in all four angle quadrants in the study eye&#xD;
&#xD;
          -  Subject is able and willing to attend all scheduled follow-up exams&#xD;
&#xD;
          -  Subject understands and signs the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects presenting 1 or more of the following criteria will not be enrolled in the&#xD;
             trial:&#xD;
&#xD;
               -  Ocular conditions with a poorer prognosis in the fellow eye than in the study eye&#xD;
&#xD;
               -  Closed angle forms of glaucoma in either eye&#xD;
&#xD;
               -  Congenital or developmental glaucoma in either eye&#xD;
&#xD;
               -  Other secondary glaucoma (such as neovascular, uveitic, lens-induced,&#xD;
                  trauma-induced, or glaucoma associated with increased episcleral venous pressure)&#xD;
                  in the study eye&#xD;
&#xD;
               -  Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the&#xD;
                  study eye&#xD;
&#xD;
               -  Subject has history of penetrating keratoplasty (PKP)&#xD;
&#xD;
               -  Any previous surgery in the study eye (except for clear corneal cataract surgery)&#xD;
                  where the conjunctiva is not intact and elastic.&#xD;
&#xD;
               -  Any ocular disease or history in study eye such as severe dry eye, active&#xD;
                  proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and&#xD;
                  ocular pathology that may interfere with accurate IOP measurements&#xD;
&#xD;
               -  Prior surgery for an ab-interno or ab-externo device implanted in or through the&#xD;
                  Schlemm's canal in the study eye.&#xD;
&#xD;
               -  Use of oral hypotensive medication for glaucoma for treatment of the fellow eye&#xD;
&#xD;
               -  Less than the minimum visual function required for driving in the fellow eye:&#xD;
                  best-corrected visual acuity worse than 20/40 (Snellen equivalent) or Esterman&#xD;
                  visual field score less than 85%.&#xD;
&#xD;
               -  History of idiopathic or autoimmune uveitis in either eye&#xD;
&#xD;
               -  Severe trauma in study eye&#xD;
&#xD;
               -  active iris neovascularization, previous cyclodestructive procedure, prior&#xD;
                  scleral buckling procedure, presence of silicone oil, need for glaucoma surgery&#xD;
                  combined with other ocular procedures or anticipated need for additional ocular&#xD;
                  surgery in study eye within 12 month period&#xD;
&#xD;
               -  Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in&#xD;
                  study eye&#xD;
&#xD;
               -  Aphakia&#xD;
&#xD;
               -  Prior vitreoretinal surgery in study eye&#xD;
&#xD;
               -  Clinically significant ocular inflammation or infection within 90 days prior to&#xD;
                  screening&#xD;
&#xD;
               -  Unable to discontinue use of blood thinners in accordance with surgeon's standard&#xD;
                  preoperative instructions&#xD;
&#xD;
               -  Uncontrolled systemic disease that in the opinion of the investigator would put&#xD;
                  the subject's health at risk and/or prevent the subject from completing all study&#xD;
                  visits&#xD;
&#xD;
               -  Current participation or participation in another investigational drug or device&#xD;
                  clinical trial within the last 30 days before screening visit&#xD;
&#xD;
               -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cotlear, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Cotlear, MD</last_name>
    <phone>972-3-5302872</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Goldschleger Eye Institute, The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Cotlear</last_name>
      <phone>972-3-5302872</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 31, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

